These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 20852166)

  • 1. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration.
    Kumar A; Mann HJ
    Am J Health Syst Pharm; 2010 Oct; 67(19):1640-4. PubMed ID: 20852166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration.
    Housman ST; Tessier PR; Nicolau DP; Kuti JL
    Am J Health Syst Pharm; 2011 Dec; 68(23):2265-70. PubMed ID: 22095816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.
    Correard F; Savry A; Gauthier-Villano L; Pisano P; Pourroy B
    Am J Health Syst Pharm; 2014 Aug; 71(15):1288-91. PubMed ID: 25027536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
    Chan P; Bishop A; Kupiec TC; Trissel LA; Gole D; Jimidar IM; Vermeersch H
    Am J Health Syst Pharm; 2008 Aug; 65(16):1545-51. PubMed ID: 18693210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physical compatibility of ceftolozane-tazobactam with selected i.v. drugs during simulated Y-site administration.
    Thabit AK; Hamada Y; Nicolau DP
    Am J Health Syst Pharm; 2017 Jan; 74(1):e47-e54. PubMed ID: 28007721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physical compatibility of tedizolid phosphate with selected i.v. drugs during simulated Y-site administration.
    Ghazi I; Hamada Y; Nicolau DP
    Am J Health Syst Pharm; 2016 Nov; 73(21):1769-1776. PubMed ID: 27769972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physical and chemical compatibility of drotrecogin alfa (activated) with 34 drugs during simulated Y-site administration.
    Mann HJ; Demmon SL; Boelk DA; Payne CA; Effron MB; Rajagopalan N; Williams MD; Beck GM; Gopalrathnam G
    Am J Health Syst Pharm; 2004 Dec; 61(24):2664-71. PubMed ID: 15646701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nefopam hydrochloride compatibility and stability with selected proton pump inhibitors in bionolyte G5 injection for intravenous infusion.
    Kambia NK; Luyckx M; Dine T; Dupin-Spriet T; Gressier B; Brunet C
    J Clin Pharm Ther; 2009 Feb; 34(1):25-31. PubMed ID: 19125900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
    Singh BN; Dedhiya MG; DiNunzio J; Chan P; Kupiec TC; Trissel LA; Laudano JB
    Am J Health Syst Pharm; 2011 Nov; 68(22):2163-9. PubMed ID: 22058102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visual compatibility of colistin injection with other antibiotics during simulated Y-site administration.
    Katip W
    Am J Health Syst Pharm; 2017 Jul; 74(14):1099-1102. PubMed ID: 28687555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stability and compatibility of fluorouracil and mannitol during simulated Y-site administration.
    Woloschuk DM; Wermeling JR; Pruemer JM
    Am J Hosp Pharm; 1991 Oct; 48(10):2158-60. PubMed ID: 1781472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
    Asempa TE; Avery LM; Kidd JM; Kuti JL; Nicolau DP
    Am J Health Syst Pharm; 2018 Jul; 75(14):1048-1056. PubMed ID: 29895521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
    Trissel LA; Gilbert DL; Martinez JF
    Am J Health Syst Pharm; 1997 Jan; 54(1):56-60. PubMed ID: 9117791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
    Monogue ML; Almarzoky Abuhussain SS; Kuti JL; Nicolau DP
    Am J Health Syst Pharm; 2018 Jan; 75(1):e36-e44. PubMed ID: 29273611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compatibility of cefepime and vancomycin during simulated Y-site administration of prolonged infusion.
    Berti AD; Hutson PR; Schulz LT; Webb AP; Rose WE
    Am J Health Syst Pharm; 2015 Mar; 72(5):390-5. PubMed ID: 25694414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
    Trissel LA; Saenz CA; Ogundele AB; Ingram DS
    Am J Health Syst Pharm; 2004 Nov; 61(21):2289-93. PubMed ID: 15552637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
    Trissel LA; Martinez JF
    Am J Health Syst Pharm; 1996 May; 53(9):1041-5. PubMed ID: 8744467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients.
    Canann D; Tyler LS; Barker B; Condie C
    Am J Health Syst Pharm; 2009 Apr; 66(8):727-9. PubMed ID: 19336832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection.
    Trissel LA; Bready BB
    Am J Hosp Pharm; 1992 Jul; 49(7):1716-9. PubMed ID: 1352424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
    Trissel LA; Martinez JF; Simmons M
    J Am Pharm Assoc (Wash); 1999; 39(2):141-5. PubMed ID: 10079649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.